These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 20040311)
21. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease. Han SO; Li S; Bird A; Koeberl D Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913 [TBL] [Abstract][Full Text] [Related]
22. Improved efficacy of a next-generation ERT in murine Pompe disease. Xu S; Lun Y; Frascella M; Garcia A; Soska R; Nair A; Ponery AS; Schilling A; Feng J; Tuske S; Valle MCD; Martina JA; Ralston E; Gotschall R; Valenzano KJ; Puertollano R; Do HV; Raben N; Khanna R JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843882 [TBL] [Abstract][Full Text] [Related]
23. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD). Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618 [TBL] [Abstract][Full Text] [Related]
24. Vacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy. Pascarella A; Terracciano C; Farina O; Lombardi L; Esposito T; Napolitano F; Franzese G; Panella G; Tuccillo F; la Marca G; Bernardini S; Boffo S; Giordano A; Di Iorio G; Melone MAB; Sampaolo S J Cell Physiol; 2018 Aug; 233(8):5829-5837. PubMed ID: 29215735 [TBL] [Abstract][Full Text] [Related]
25. Therapeutic Benefit of Autophagy Modulation in Pompe Disease. Lim JA; Sun B; Puertollano R; Raben N Mol Ther; 2018 Jul; 26(7):1783-1796. PubMed ID: 29804932 [TBL] [Abstract][Full Text] [Related]